Introducing (2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone 2-hydroxybenzoate: A Trusted Backbone for Nucleoside Analogue Development

Our Hands-On Experience with Manufacturing and Improving (2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone 2-hydroxybenzoate

For decades, the chemical and pharmaceutical worlds have witnessed an ongoing push for safer, more reliable active pharmaceutical ingredients (APIs) and their key intermediates. As a manufacturer directly involved in the day-to-day syntheses, process improvement, and analytical quality control of specialized nucleoside compounds, the road often winds through detailed chemical pathways and demanding quality benchmarks. Among these molecules, (2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone 2-hydroxybenzoate stands out for its unique structure and proven reliability in research and industrial applications.

Model, Form, and Key Specifications Based on Real-World Manufacturing

The product we discuss here is the 2-hydroxybenzoate salt of a pivotal nucleoside intermediate. Routine batch synthesis under current Good Manufacturing Practices (cGMP) produces a white to off-white crystalline solid, with product lots differing slightly depending on crystal habit and water content. Analytical verification through HPLC, NMR, and HRMS confirms structure, stereochemistry, and high levels of purity. Control of the 2R-cis configuration is achieved through stereoselective steps, minimizing formation of diastereomers and ensuring batch consistency. Typical batches yield purity upwards of 99% (HPLC area normalization), with residual solvent and elemental analyses falling within tight, predetermined limits. Laboratory and commercial-scale experience has revealed that robust crystallization and filtration under controlled low-solvent conditions reduce byproduct contamination significantly, a detail that often gets lost among distributors who never see raw crystal isolation firsthand.

The product’s molecular weight sits at 352.34 g/mol, which, as any seasoned process chemist knows, carries implications for solvent loading, trigger points for precipitation, and storage density. Handling experience also makes clear that this salt form offers greater ease in weighing and dissolution than free base counterparts. Flow handling with moderate humidity control (30-45%) avoids caking and facilitates both bench and pilot delivery. Our operators, frequently on the plant floor, note the practicality of unmistakable crystalline appearance for visual checks—one of those overlooked but valuable real-world quality cues.

Why 2-Hydroxybenzoate Salt? Insights from Process Development

During our extensive product development work, we’ve seen the impact salt selection has on everything from crystallization to solubility and subsequent downstream reactions. The 2-hydroxybenzoate salt of this nucleoside analogue brings unique benefits that become clear during real processing. Purification routes, which form the backbone of API manufacturing, demand separation of closely related impurities and isomers. The benzoate counterion imparts robust lattice stability, leading to solid formation with lower hygroscopicity and easier isolation, minimizing costly repurification cycles.

Such practical advantages emerge first in the tank and on the benchtop. In head-to-head trials with hydrochloride and mesylate alternatives, the 2-hydroxybenzoate form delivers improved batch yield and more straightforward washability, significantly lowering solvent waste. Experienced technicians regularly flag this trait because it means less solvent recapture and easier logistics—details that matter when moving past small-scale chemistry and into multi-kilogram processes. From firsthand troubleshooting, we have encountered fewer filtration and stickiness issues with this salt, a boon for operational simplicity. This saves substantial labor and time that would otherwise go into unclogging equipment or reprocessing sticky solids.

Usage in Research and Industry from the Manufacturer’s Perspective

Most of our production volume goes to pharmaceutical research labs, both for preclinical synthesis of active nucleoside analogues and as an intermediate for the scale-up of therapies targeting viral infections. Several research teams have shared feedback directly with our technical leaders—consistent crystalline form, reliable purity, and low byproduct profiles make multi-step synthesis much smoother. Even seemingly minor adjustments—drying protocols, choice of recrystallization solvent, or grind size—often spell the difference between successful reaction and failed batch. Over many batches, we’ve learned how to tune these parameters, reducing impurity formation and making downstream steps less burdensome for our customers.

In addition to antiviral nucleoside synthesis, chemical researchers turn to this salt for reference standards, structure-activity relationship (SAR) studies, and SAR-guided lead optimization. The compound’s well-defined structure and analytical clarity make it highly attractive for academic research and industrial labs where time spent troubleshooting starting material issues eats up valuable development hours. End-users in our feedback network cite prompt dissolution, consistent melting profiles, and limited polymorphic behavior—harvested directly from batches that went through actual full-scale crystallization and drying cycles, not just analytical test-tube trials.

Comparing to Other Products – An Insider’s View

Only hands-on experience with batch processing and continuous product improvement reveals the subtle but important differences between salt forms and process routes. We have processed similar nucleoside analogues in both hydrochloride and free base forms, as well as lyophilized amorphous versions. Across dozens of comparative product trials, the 2-hydroxybenzoate salt delivers a better trade-off in filterability and shelf stability without the high water uptake seen in some hydrochloride variants, which often demand chemical dryers and complicated storage systems.

From the operator’s standpoint, hydrochloride and mesylate forms bring added risk of hydrolysis and undesirable byproduct build-up, especially when solution sits for extended periods in non-neutral pH. Storage feedback from clients and our own warehouses indicates that the 2-hydroxybenzoate form retains its solid, easily handled character over wider ranges of temperature and time, reducing physical degradation and ensuring more reproducible analytical results in later use. Our records show fewer deviations and customer complaints originating from this product compared to related intermediates—results earned by repeated synthesis, not theoretical modeling.

By working closely with formulation scientists, we noticed that the enhanced stability translates into simpler analytical verification both during release testing and secondary formulation steps. In practical workflow scenarios, this means fewer batch holds and analytical retests, streamlining the development of nucleoside-based drug candidates—real benefits documented across dozens of supply chain partners, not just in-house validation. Every chemical manufacturer faces the reality that even slight instability or poor flow cause loss of batch or necessitate expensive rework. Based on repeated scale-ups, this salt form lets us reduce such avoidable costs.

Impact on Downstream Synthesis: Manufacturing Realities

From experience, switching nucleoside intermediates mid-campaign often introduces unanticipated delays or regulatory hurdles. Once a reliable form is in place, maintaining physical and chemical consistency greatly reduces qualification times for new batch records and regulatory documentation. The 2-hydroxybenzoate salt of this compound has become a mainstay in our plant because operators and development chemists know what to expect. Repeatability counts—every batch we release brings confidence that downstream coupling reactions, protecting group manipulations, and coupling with phosphoramidite intermediates proceed with higher stepwise yields. In feedback from contract manufacturing teams, we learned that this translates to fewer failed lots at the oligonucleotide or final API stage.

Handling on the production floor has shown that this salt variant takes up less environmental moisture and stays free-flowing after several months under standard warehouse conditions. Unlike the more fragile free base, which develops clumping and surface degradation, our product remains consistent, facing minimal lot-to-lot variability. This is where hands-on manufacturing practice distinguishes optimal product: we look at flow characteristics, particle homogeneity from mill to packing station, and resistance to mechanical stress, not only chemical purity or documentation.

Quality Control and Analytical Assurances: Built from the Ground Up

Quality control starts in the reaction vessel and follows through the entire product life cycle. Trained analysts track every batch using up-to-date chromatography, mass spectrometry, and spectroscopic techniques. We address trace contaminants, isomeric impurities, and solvent residues at each step, not only at final release. This upstream attention prevents issues in customers’ downstream chemistry, a lesson learned through plenty of direct technical exchanges with research and development scientists across multiple international markets.

Stability studies conducted internally demonstrate robust shelf life, with isolated samples from real shipments and storage runs tested for degradation and water uptake. Analytical experience guides our bounds for acceptance—actual deviations recorded in the plant define process change needs, not theoretical specifications. These real-world checks generate the confidence that comes only from repeated, verifiable batch-to-batch quality, evidenced by certificates of analysis built from factory histories rather than generic templates.

Beyond statutory batch records, our practice incorporates trending analyses, root cause investigations for non-conformances, and feedback loops from customer technical service. These iterative improvements, refined through involvement at every stage from raw material procurement to final product packaging, minimize batch variability and actualize the full potential of this compound in demanding research and production environments.

Supporting Pharmaceutical Innovation and Advanced Research

Years in chemical manufacturing reveal how crucial it is for customers to receive exactly what they ordered, with batch reproducibility and purity at levels supporting both discovery and regulatory filings. We participate in joint development discussions, giving advice on crystallization parameters, reconstitution protocols, and even troubleshooting solvent screening at the formulation scale, based on process observations collected during daily operations. Customers have confirmed that the improvements made during our thermal stability and process optimization projects have helped increase throughput in their drug candidate evaluation phases.

Collaborations with development chemists and academic leaders often center on the precise reactivity of this compound and its performance under physiological conditions. The real test of a manufacturing process lies not just in producing compliant product, but also in incorporating practical lessons from hundreds of campaign runs. Based on ramp-up experience, modifications in filtration and washing steps, and the switch to 2-hydroxybenzoate, yield higher-purity material with greater predictable reactivity—a result valued above incremental gain in theoretical yield alone.

Addressing Issues in Scale and Sourcing: Lessons Learned in Manufacture

The process journey takes many turns, from raw material bottlenecks to unexpected plant shutdowns. Across recent years, our supply chain faced global disruptions and surges in demand for nucleoside intermediates. The in-house control of (2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone 2-hydroxybenzoate allowed us to keep supply strong, sidestepping shortages that have delayed critical projects for many pharma partners. Direct oversight of underlying raw material procurement, coupled with native technical knowledge, prevents vulnerability to vendor-peculiarities, counterfeit material, or ambiguously labeled street-sourced alternatives.

We address scaling issues by routinely validating process parameters at both laboratory and plant scale. In practice, differences in agitation, heating, and isolation rates show up quickly—and so do their effects on purity and form. Only by proper adaptation to plant equipment, cross-checking repeatability across both small and large reactors, can new process refinements move from theoretical improvement to reliable, daily production. While paper procedures help, nothing beats direct plant-floor confirmation, and our team’s dedication continues to shape protocols that respond to these real-world constraints.

Future Directions and Ongoing Improvement in Nucleoside Intermediate Manufacturing

Manufacturing competitive and reliable nucleoside intermediates means never standing still. Regular investment in analytical assets, process optimization efforts, and talent development underpins our ability to serve both new biotech startups and established pharmaceutical producers. The lessons learned in direct interaction with this compound—addressing issues like improved solvent recovery, energy use minimization, and material throughput—shape our plant’s ongoing process refinements. Every cycle of batch improvement draws from data generated and problems solved in-house—technical literature augments these lessons, but plant-based experience remains our core driver.

As clinical and research fields turn toward ever-more-complex nucleoside structures, reliable access to foundational intermediates becomes more pivotal. Through controlled manufacturing, open data-sharing, and proactive feedback gathering, we continue to advance the consistency and scalability of (2r-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone 2-hydroxybenzoate. Vigilant improvement remains crucial as we respond to new regulatory, application, and operational demands. Commitment to fully traceable, repeat-tested process control translates directly into end-user confidence—not merely in the documentation, but in the real, batch-to-batch product delivered worldwide.

Conclusion: A Manufacturer’s Faith in Reliable Chemistry

The story of this compound involves more than technical details or regulatory language. Real reliance in research, scaled production, and clinical application comes from careful manufacturing, deep technical understanding, and continued, face-to-face improvement. Our multi-year experience—through process bottlenecks, innovation cycles, and real-world troubleshooting—grounds the confidence end-users place in every shipment. Wide-ranging applications across antiviral drug development, nucleoside synthesis, and chemical innovation are only possible thanks to the consistent quality and performance built into every batch. For research and commercial teams alike, this compound stands as an example of what focused manufacturing and practical know-how can achieve in support of the next generation of pharmaceutical advancements.